glp-1 obesity drug news today september 29 2025 Agonists Market Report 2025-2033, By Product, Molecule, and Geo GLP-1 Agonists Market Report 2025-2033,

Dietary protein acts as the primary building block for muscle repair and synthesis

Glucagon-like peptide-1 receptor agonist (GLP-1RAs) and more recently Twin-Cretins (GLP+GIP) are frequently used for patients with diabetes and associated obesity

These medications have increased in popularity over the past few years, and there is a lot of interest - especially in women who are wanting to lost weight postpartum

What many users don't realize is that dehydration and electrolyte depletion drive most of these symptomsand the righ

2020 global estimate and projected number of adults through 2035 with an overweight BMI [1]. Obesity is a significant independent risk factor contributing to numerous chronic conditions, including diabetes, hypertension, cardiovascular disease, and obstructive sleep apnea syndrome

Primary outcomes included serious adverse events and retained gastric products based on patient records, procedure reports, and procedural videos